Financial Summary

BioNTech SE  (BNTX)  $102.95    (%)

  • Symbol
    BNTX
    Price
    102.95$
    Beta
    0
    Volume Avrg.
    4088025
    Market Cap
    24788918300
    Last Div
    0
    Range
    28.0-131.0
    Changes
    -1.75
    Changes Percentage
    Exchange
    NasdaqGS
    Industry
    Biotechnology
    Ceo
    Prof. Ugur Sahin M.D.
    Sector
    Healthcare

About company

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc., Sanofi S.A., Genmab A/S, Genevant Sciences GmbH, Eli Lilly and Company, Bayer AG, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in Mainz, Germany.


Income Statement

Year Revenue Cost of revenues Gross profit Operating expensess Operating incomes Interest expense Income tax expenses Earnings before taxs Net income Earnings per share basics Earnings per share diluteds Dividend per shares Gross margins EBIT margins Profit margins EBITDA EBIT Earnings Before Tax Margins Net Profit Margins
2020 274515.00 169559.00 104956.00 38668.00 66288.00 0.00 968.00 67091.00 57411.00 3.31 3.28 0.803333414346 0.382332477278109 0.300289471658 0.209136112780722 77344.00 66288.00 0.244398302460703 0.209136112780722
2019 260174.00 161782.00 98392.00 34462.00 6393.00 3576.00 10481.00 65737.00 55256.00 2.97145 2.97145 3.03705403822 0.378178 0.245720171885 0.212381 8186.00 6393.00 0.252666 0.212381
2018 265595.00 163756.00 101839.00 30941.00 70898.00 324.00 11872.00 72903.00 59531.00 2.97649 2.97649 2.74234021698 0.383437 0.266940266195 0.224142 85546.00 70898.00 0.274489 0.224142
2017 229234.00 141048.00 88186.00 26842.00 61344.00 2323.00 15738.00 64089.00 48351.00 2.3175 2.3025 2.43140686849 0.384698604918991 0.267604282087 0.210924208450753 76569.00 61344.00 0.27957894553164 0.210924208450753
2016 215639.00 131376.00 84263.00 24239.00 60024.00 1456.00 15685.00 61372.00 45687.00 2.07658 2.07658 2.20897805039 0.39076 0.278354101067 0.211868 73333.00 60024.00 0.284605 0.211868
2015 233715.00 140089.00 93626.00 22396.00 7123.00 733.00 19121.00 72515.00 53394.00 2.30422 2.30422 1.99566067658 0.400599 0.304772907173 0.228458 84505.00 7123.00 0.310271 0.228458
2014 182795.00 112258.00 70537.00 18034.00 52503.00 384.00 13973.00 53483.00 3951.00 1.61318 1.61318 1.817183144 0.38588 0.287223392325 0.216144 61813.00 52503.00 0.292585 0.216144
2013 17091.00 106606.00 64304.00 15305.00 48999.00 136.00 13118.00 50155.00 37037.00 1.41969 1.41969 11.338876116 0.376245 0.286694751624 0.216705 57048.00 48999.00 0.293459 0.216705
2012 156508.00 87846.00 68662.00 13421.00 55241.00 1088.00 1403.00 55763.00 41733.00 1.57673 1.57673 2.63181556135 0.438712 0.35295959312 0.266651 60128.00 55241.00 0.356295 0.266651
2011 108249.00 64431.00 43818.00 10028.00 3379.00 519.00 8283.00 34205.00 25922.00 0.98833 0.98833 0.0 0.404789 0.312150689614 0.239466 36538.00 3379.00 0.315984 0.239466
2010 65225.00 39541.00 25684.00 7299.00 18385.00 311.00 4527.00 1854.00 14013.00 0.54121 0.54121 0.0 0.393775 0.281870448448 0.214841 19878.00 18385.00 0.284247 0.214841
2009 42905.00 25683.00 17222.00 5482.00 1174.00 407.00 3831.00 12066.00 8235.00 0.32426 0.32426 0.0 0.401398 0.2812 0.191936 13207.00 12066.00 0.281226 0.191936
Year202020192018201720162015201420132012201120102009
Revenue274515.00260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues169559.00161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 104956.00 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess38668.0034462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense0.003576.00324.002323.001456.00733.00384.00136.001088.00519.00311.00407.00
Income tax expenses968.0010481.0011872.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs67091.0065737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income57411.0055256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics3.312.971452.976492.31752.076582.304221.613181.419691.576730.988330.541210.32426
Earnings per share diluteds3.282.971452.976492.30252.076582.304221.613181.419691.576730.988330.541210.32426
Dividend per shares0.83.042.742.432.2121.8211.342.63000
Gross margins0.380.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.30.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.210.210.220.210.210.230.220.220.270.240.210.19
EBITDA77344.008186.0085546.0076569.0073333.0084505.0061813.0057048.0060128.0036538.0019878.0013207.00
EBIT66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.240.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.210.210.220.210.210.230.220.220.270.240.210.19